摘要
目的比较经肝动脉栓塞化疗(TACE)联合125I粒子与单独TACE治疗肝细胞癌(HCC)的临床疗效。方法计算机检索PubMed、Cochrane Library、EM-base、Web of Science、CBM、VIP、Wan Fang Data、CNKI等数据库,纳入TACE联合125I治疗HCC的临床对照试验,按Cochrane系统评价方法评价纳入研究质量,采用RevMan 5.0软件进行Meta分析。结果按照入选标准,纳入5个研究共431例。结果显示,TACE联合125I组在0.5年生存率(OR=11.19,95%CI:4.48~27.95,P<0.01)、1年生存率(OR=4.55,95%CI:2.63~7.88,P<0.01)、总有效率(OR=2.07,95%CI:1.91~3.08,P<0.01)、AFP下降(OR=-57.98,95%CI:-74.01^-30.22,P<0.01)均优于单纯TACE组,差异有统计学意义。结论与单独TACE治疗相比,TACE联合125I治疗无法手术切除肝细胞癌能提高局部疗效及患者生存率。
Objective To compare the clinical effect of combination of transcathether arterial chemoembolization(TACE) and125I seeds with TACE alone for unresectable hepatocellular carcinoma(HCC). Method PubMed, the Cochrane Library, EM-base, Web of Science, CBM, VIP, Wan Fang Data, CNKI database were used for searching literatures about controlled clinical trials of comparison of the combination of TACE and125I seeds with TACE alone for unresectable HCC. The research quality was evaluated according to the Cochrane system evaluation method. RevMan 5.0 was used for Meta analysis.Results A total of 431 patients in five studies were included in this study. The meta analysis showed that the clinical effect of the combination of TACE and125I seeds for treatment of unresectable HCC were significantly better than that of TACE alone, including the 0.5-year survival rate(OR=11.19, 95% CI:4.48 ~27.95, P <0.00001), 1-year survival rate(OR =4.55, 95% CI: 2.63 ~7.88, P <0.00001), total effective rate(OR=2.07, 95% CI: 1.91~3.08, P<0.00001), AFP decrease(OR=57.98, 95% CI: 74.01~30.22, P<0.00001). Conclusion Compared with TACE alone, the combination of TACE with 125I seeds for the treatment of unresectable HCC has advantages in improving the local efficacy and overall survival.
出处
《消化肿瘤杂志（电子版）》
2013年第2期114-118,共5页
Journal of Digestive Oncology(Electronic Version)
基金
横向经费(Y-B2012-012)
